Next Article in Journal
Ethosomes and Transethosomes as Cutaneous Delivery Systems for Quercetin: A Preliminary Study on Melanoma Cells
Previous Article in Journal
Click-Chemistry Cross-Linking of Hyaluronan Graft Copolymers
Previous Article in Special Issue
Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
 
 
Review

The Role of the Kinase Inhibitors in Thyroid Cancers

1
Department of Experimental Medicine, Università degli Studi della Campania L. Vanvitelli, 80138 Napoli, Italy
2
School of Medicine, University of Pisa, 56124 Pisa, Italy
3
Department of Precision Medicine, Università degli Studi della Campania L. Vanvitelli, 80138 Napoli, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: James J. Moon
Pharmaceutics 2022, 14(5), 1040; https://doi.org/10.3390/pharmaceutics14051040
Received: 16 March 2022 / Revised: 27 April 2022 / Accepted: 8 May 2022 / Published: 11 May 2022
(This article belongs to the Special Issue Cancer Therapy Resistance: Choosing Kinase Inhibitors)
Thyroid cancer is the most common endocrine malignancy, accounting for about 3% of all cancer cases each year worldwide with increasing incidence, but with the mortality remaining stable at low levels. This contradiction is due to overdiagnosis of indolent neoplasms identified by neck ultrasound screening that would remain otherwise asymptomatic. Differentiated thyroid carcinomas (DTCs) are almost curable for 95% with a good prognosis. However, 5% of these tumours worsened toward aggressive forms: large tumours with extravasal invasion, either with regional lymph node or distant metastasis, that represent a serious clinical challenge. The unveiling of the genomic landscape of these tumours shows that the most frequent mutations occur in tyrosine kinase receptors (RET), in components of the MAPK/PI3K signalling pathway (RAS and BRAF) or chromosomal rearrangements (RET/PTC and NTRK hybrids); thus, tyrosine-kinase inhibitor (TKI) treatments arose in the last decade as the most effective therapeutic option for these aggressive tumours to mitigate the MAPK/PI3K activation. In this review, we summarize the variants of malignant thyroid cancers, the molecular mechanisms and factors known to contribute to thyroid cell plasticity and the approved drugs in the clinical trials and those under investigation, providing an overview of available treatments toward a genome-driven oncology, the only opportunity to beat cancer eventually through tailoring the therapy to individual genetic alterations. However, radiotherapeutic and chemotherapeutic resistances to these anticancer treatments are common and, wherever possible, we discuss these issues. View Full-Text
Keywords: cancer; thyroid; TKI therapy; chemoresistance; trials cancer; thyroid; TKI therapy; chemoresistance; trials
Show Figures

Figure 1

MDPI and ACS Style

Cuomo, F.; Giani, C.; Cobellis, G. The Role of the Kinase Inhibitors in Thyroid Cancers. Pharmaceutics 2022, 14, 1040. https://doi.org/10.3390/pharmaceutics14051040

AMA Style

Cuomo F, Giani C, Cobellis G. The Role of the Kinase Inhibitors in Thyroid Cancers. Pharmaceutics. 2022; 14(5):1040. https://doi.org/10.3390/pharmaceutics14051040

Chicago/Turabian Style

Cuomo, Francesca, Claudio Giani, and Gilda Cobellis. 2022. "The Role of the Kinase Inhibitors in Thyroid Cancers" Pharmaceutics 14, no. 5: 1040. https://doi.org/10.3390/pharmaceutics14051040

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop